Meta-analysis of metabolic syndrome and benign prostatic hyperplasia in Chinese patients

Zou, Chen; Gong, Dandan; Fang, Na; Fan, Yu

doi:10.1007/s00345-015-1626-0

Cited by 33 publications

(32 citation statements)

References 26 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, Zoe et al reported higher PSA levels in BPH patients with MtS (23). Our findings were not in the same line with DiBello et al (22) but, were similar with results of Zou et al (23). There was higher PSA levels in Group 1 than in Group 2 without statistical significance.…”

Section: Discussionsupporting

confidence: 82%

Preliminary assessment of neck circumference in Benign Prostatic Hyperplasia in patients with metabolic syndrome

Akın¹,

Gulmez²,

Ateş

et al. 2016

European Urology Supplements

View full text Add to dashboard Cite

ARTICLE INFO ______________________________________________________________ ______________________Objectives: To investigate the impact of neck circumference (NC) in the treatment of bening prostatic hyperplasia (BPH) patients with metabolic syndrome (MtS). Additionally, we determined dose response to alpha-blockers and cut-off values for NC and waist circumference (WC), in these patients. Materials and Methods: Non-randomized, open-labelled, and multi-centre study was conducted between March 2014 and September 2015. The BPH patients were enrolled and were divided into 2 groups: with MtS (Group 1; n=94) and without MtS (Group 2; n=103). Demographic data, anthropometric measurements, blood analyses, uroflowmetric parameters, post voiding residual urine (PVR), prostate volume, quality of life (QoL) index, NC and WC were recorded. Both groups were administered oral alphablockers and response to treatment was evaluated. Receiver-operating characteristic (ROC) curves were obtained and significant p was p<0.05. Results: In total, 197 patients were enrolled with mean age of 60.5±8.1 years. Mean NC and WC were higher in MtS patients (p<0.001). Uroflowmetry parameters and QoL indexes were comparable between groups before treatment. International prostate symptom score, uroflowmetry parameters, and QoL significant improved in Group 2 than Group 1, at 1 st and 6 th months of treatment with alpha-blockers. Success rate of treatment was significant higher in Group 2 than Group 1 (p<0.001). Cut-off values were 42.5cm and 113.5cm for NC and WC respectively, for response to alpha-blockers in BPH patients with MtS. Conclusions: MtS can be related with BPH and can negatively affect the response to alpha-blocker treatment. NC can be used for predicting response to alpha-blocker treatment in BPH patients with MtS.

show abstract

Section: Discussionsupporting

confidence: 82%

Preliminary assessment of neck circumference in Benign Prostatic Hyperplasia in patients with metabolic syndrome

Akın¹,

Gulmez²,

Ateş

et al. 2016

European Urology Supplements

View full text Add to dashboard Cite

show abstract

“…Previous studies have suggested that BPH may be regarded as a new aspect of MetS, and compensatory increased fasting plasma insulin is a promoter of BPH [5]. Although a positive association has been reported between MetS and prostate growth [6,7], it is not clear whether MetS may have an effect on the clinical progression of BPH. Clinical aspects including patient age, prostate volume (PV), International Prostate Symptom Score (IPSS), serum prostate specific antigen (PSA) and maximum urine flow rate (Q max ) have been identified as risk factors in the clinical progression of BPH.…”

Section: Introductionmentioning

confidence: 85%

The Relationship between the Clinical Progression of Benign Prostatic Hyperplasia and Metabolic Syndrome: A Prospective Study

Zhou

Yang

et al. 2016

Urol Int

View full text Add to dashboard Cite

Objective: To investigate whether metabolic syndrome (MetS) may be associated with the clinical progression of benign prostatic hyperplasia (BPH). Methods: A total of 525 community-dwelling men (aged 45-78) with lower urinary tract symptoms (LUTS) who had complete data at 3-year follow-up were included in this prospective study. International Prostate Symptom Score (IPSS) questionnaire, prostate ultrasonography for prostate volume (PV), maximum urine flow rate (Q_max) and biological parameters were recorded. Participants were divided into a BPH with the MetS group and a BPH without the MetS group, and all received a 3-year follow-up to monitor possible correlations between LUTS/BPH clinical progression and MetS. Results: The results showed that MetS was associated with IPSS, Q_max and PV (p < 0.05) after 3-year follow-up. The mean change of IPSS, PV and Q_max were positively and negatively correlated with time in the BPH with MetS group during the 3-year follow-up. In addition, the BPH clinical progression rate was significantly higher in the BPH with MetS group, compared with the BPH without MetS group (p < 0.05). Diabetes mellitus (DM) and hypertension were related to increased risk of BPH clinical progression. Conclusions: The present results suggest that MetS, in particular, DM and hypertension, may accelerate the clinical progression of BPH in community-dwelling middle-aged and older men.

show abstract

“…There are many clinical and epidemiological studies about the relation between MetS and certain chronic diseases including BPH [11][12][13][14][15][16] . The neutrophil-lymphocyte ratio (NLR) has been proposed as an indicator of systemic inflammatory response and MetS as an indicator in some recent clinical studies [17][18][19][20] .…”

mentioning

confidence: 99%

Association between Benign Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome

et al. 2016

View full text Add to dashboard Cite

Aim: There is a large body of evidence of clinical studies regarding the relation between metabolic syndrome (MetS) and benign prostatic hyperplasia (BPH)-related lower urinary tract symptoms (LUTS) in men. A possible link between inflammation and these 2 clinical entities has also been proposed. Here, we aimed at evaluating the role of neutrophil-lymphocyte ratio (NLR), an indicator of inflammation and MetS, in the pathogenesis of LUTS and other BPH-related parameters. Method: We evaluated 244 patients with benign prostate hyperplasia admitted to our outpatient clinic between January 2014 and June 2015. NLR was calculated from the peripheral blood sample for all patients. Patients' anthropometric characteristics, serum lipid levels, waist circumferences, total prostate-specific antigen (PSA) and testosterone values, prostate volumes, max values and International Prostate Symptom Score (IPSS) were recorded. All statistical analyses were conducted by SPSS version 17.0 package program, and p value <0.05 was chosen as the criterion for statistical significance. Results: There was statistical significance between NLR and patients with severe IPSS score (>20) and over age 60 years (p = 0.02). Patients younger than 60 years had statistical significance between NLR and PSA <2.5 ng/dl (p = 0.004). When body mass index was selected, there was statistical significance between prostate volume <35 ml (p = 0.009) and age >60 years (p = 0.028). If 60 years of age was selected as cut-off value, there is statistical significance between age and severe IPSS, and in terms of mild erectile dysfunction, PSA >2.5 ng/dl, and prostate volume >35 ml. Conclusion: We found positive correlation between NLR and severe symptoms and progression of BPH. In this manner, anti-inflammatory therapy could contribute to the medical treatment of BPH. Higher NLR may be a candidate marker for severity of symptoms in BPH patients.

show abstract

Meta-analysis of metabolic syndrome and benign prostatic hyperplasia in Chinese patients

Abstract: This meta-analysis supports that the presence of MetS increases total prostate volume and annual prostate growth rate in Chinese BPH patients. Future studies are needed to explain the detailed underlying mechanisms.

Cited by 33 publications

References 26 publications

Preliminary assessment of neck circumference in Benign Prostatic Hyperplasia in patients with metabolic syndrome

Preliminary assessment of neck circumference in Benign Prostatic Hyperplasia in patients with metabolic syndrome

The Relationship between the Clinical Progression of Benign Prostatic Hyperplasia and Metabolic Syndrome: A Prospective Study

Association between Benign Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome

Contact Info

Product

Resources

About